{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:50:47Z","timestamp":1790905847417,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,29]]},"DOI":"10.7759\/cureus.51304","type":"journal-article","created":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T00:51:48Z","timestamp":1703897508000},"source":"Crossref","is-referenced-by-count":9,"title":["The Efficacy and Safety of Botulinum Toxin A for the Treatment of Rosacea: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Ahmed A","family":"Alsaati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalal","family":"Alsaadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina I","family":"Kinkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riam Saleh","family":"Alkhamis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walaa Abdu","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alhanouf Hassan","family":"Almathami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15122","article-title":"Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel","volume":"176","author":"Tan J","year":"2017","unstructured":"Tan J, Almeida LM, Bewley A, et al.. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017, 176:431-8. 10.1111\/bjd.15122","journal-title":"Br J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00461-0","article-title":"Rosacea treatment: review and update","volume":"11","author":"Zhang H","year":"2021","unstructured":"Zhang H, Tang K, Wang Y, Fang R, Sun Q. Rosacea treatment: review and update. Dermatol Ther (Heidelb). 2021, 11:13-24. 10.1007\/s13555-020-00461-0","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref3","article-title":"Managing rosacea in the clinic: from pathophysiology to treatment-a review of the literature","volume":"13","author":"Marchese Johnson S","year":"2020","unstructured":"Marchese Johnson S, Berg A, Barr C. Managing rosacea in the clinic: from pathophysiology to treatment-a review of the literature. J Clin Aesthet Dermatol. 2020, 13:S17-22.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.08.436","article-title":"Innate immune dysfunction in rosacea promotes photosensitivity and vascular adhesion molecule expression","volume":"140","author":"Kulkarni NN","year":"2020","unstructured":"Kulkarni NN, Takahashi T, Sanford JA, et al.. Innate immune dysfunction in rosacea promotes photosensitivity and vascular adhesion molecule expression. J Invest Dermatol. 2020, 140:645-655.e6. 10.1016\/j.jid.2019.08.436","journal-title":"J Invest Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.53","article-title":"Assessment of the genetic basis of rosacea by genome-wide association study","volume":"135","author":"Chang AL","year":"2015","unstructured":"Chang AL, Raber I, Xu J, et al.. Assessment of the genetic basis of rosacea by genome-wide association study. J Invest Dermatol. 2015, 135:1548-55. 10.1038\/jid.2015.53","journal-title":"J Invest Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/dermato3040019","article-title":"Rosacea: an overview of its etiological factors, pathogenesis, classification and therapy options","volume":"3","author":"Maden S","year":"2023","unstructured":"Maden S. Rosacea: an overview of its etiological factors, pathogenesis, classification and therapy options. Dermato. 2023, 3:241-62. 10.3390\/dermato3040019","journal-title":"Dermato"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.037","article-title":"Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society Expert Committee","volume":"78","author":"Gallo RL","year":"2018","unstructured":"Gallo RL, Granstein RD, Kang S, Mannis M, Steinhoff M, Tan J, Thiboutot D. Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018, 78:148-55. 10.1016\/j.jaad.2017.08.037","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1506630","article-title":"Rosacea","volume":"377","author":"van Zuuren EJ","year":"2017","unstructured":"van Zuuren EJ. Rosacea. N Engl J Med. 2017, 377:1754-64. 10.1056\/NEJMcp1506630","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16481","article-title":"Incidence and prevalence of rosacea: a systematic review and meta-analysis","volume":"179","author":"Gether L","year":"2018","unstructured":"Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol. 2018, 179:282-9. 10.1111\/bjd.16481","journal-title":"Br J Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120625","article-title":"Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea","volume":"46","author":"Wilkin J","year":"2002","unstructured":"Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, Powell F. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002, 46:584-7. 10.1067\/mjd.2002.120625","journal-title":"J Am Acad Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14349","article-title":"Swiss S1 guideline for the treatment of rosacea","volume":"31","author":"Anzengruber F","year":"2017","unstructured":"Anzengruber F, Czernielewski J, Conrad C, et al.. Swiss S1 guideline for the treatment of rosacea. J Eur Acad Dermatol Venereol. 2017, 31:1775-91. 10.1111\/jdv.14349","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2020.08.001","article-title":"Consensus on the therapeutic management of rosacea - Brazilian Society of Dermatology","volume":"95 Suppl 1","author":"Oliveira CM","year":"2020","unstructured":"Oliveira CM, Almeida LM, Bonamigo RR, Lima CW, Bagatin E. Consensus on the therapeutic management of rosacea - Brazilian Society of Dermatology. An Bras Dermatol. 2020, 95 Suppl 1:53-69. 10.1016\/j.abd.2020.08.001","journal-title":"An Bras Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.01.077","article-title":"Standard management options for rosacea: the 2019 update by the National Rosacea Society Expert Committee","volume":"82","author":"Thiboutot D","year":"2020","unstructured":"Thiboutot D, Anderson R, Cook-Bolden F, et al.. Standard management options for rosacea: the 2019 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2020, 82:1501-10. 10.1016\/j.jaad.2020.01.077","journal-title":"J Am Acad Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18420","article-title":"Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel","volume":"182","author":"Schaller M","year":"2020","unstructured":"Schaller M, Almeida LM, Bewley A, et al.. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. Br J Dermatol. 2020, 182:1269-76. 10.1111\/bjd.18420","journal-title":"Br J Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17590","article-title":"Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments","volume":"181","author":"van Zuuren EJ","year":"2019","unstructured":"van Zuuren EJ, Fedorowicz Z, Tan J, van der Linden MM, Arents BW, Carter B, Charland L. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol. 2019, 181:65-79. 10.1111\/bjd.17590","journal-title":"Br J Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/toxins13020120","article-title":"Therapeutic use of botulinum neurotoxins in dermatology: systematic review","volume":"13","author":"Martina E","year":"2021","unstructured":"Martina E, Diotallevi F, Radi G, Campanati A, Offidani A. Therapeutic use of botulinum neurotoxins in dermatology: systematic review. Toxins (Basel). 2021, 13:10.3390\/toxins13020120","journal-title":"Toxins (Basel)"},{"key":"ref17","article-title":"A new treatment regimen for rosacea: onabotulinumtoxinA","volume":"11","author":"Dayan SH","year":"2012","unstructured":"Dayan SH, Pritzker RN, Arkins JP. A new treatment regimen for rosacea: onabotulinumtoxinA. J Drugs Dermatol. 2012, 11:76-9.","journal-title":"J Drugs Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2004.30017.x","article-title":"Botulinum toxin for the treatment of facial flushing","volume":"30","author":"Yuraitis M","year":"2004","unstructured":"Yuraitis M, Jacob CI. Botulinum toxin for the treatment of facial flushing. Dermatol Surg. 2004, 30:102-4. 10.1111\/j.1524-4725.2004.30017.x","journal-title":"Dermatol Surg"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1159\/000368773","article-title":"Botulinum toxin for the treatment of refractory erythema and flushing of rosacea","volume":"230","author":"Park KY","year":"2015","unstructured":"Park KY, Hyun MY, Jeong SY, Kim BJ, Kim MN, Hong CK. Botulinum toxin for the treatment of refractory erythema and flushing of rosacea. Dermatology. 2015, 230:299-301. 10.1159\/000368773","journal-title":"Dermatology"},{"key":"ref20","article-title":"A pilot, double-blind, placebo-controlled study to assess the efficacy and safety of incobotulinumtoxina injections in the treatment of rosacea","volume":"16","author":"Dayan SH","year":"2017","unstructured":"Dayan SH, Ashourian N, Cho K. A pilot, double-blind, placebo-controlled study to assess the efficacy and safety of incobotulinumtoxina injections in the treatment of rosacea. J Drugs Dermatol. 2017, 16:549-54.","journal-title":"J Drugs Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000277","article-title":"Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea","volume":"41 Suppl 1","author":"Bloom BS","year":"2015","unstructured":"Bloom BS, Payongayong L, Mourin A, Goldberg DJ. Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea. Dermatol Surg. 2015, 41 Suppl 1:S9-16. 10.1097\/DSS.0000000000000277","journal-title":"Dermatol Surg"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati A","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al.. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009, 6:e1000100. 10.1371\/journal.pmed.1000100","journal-title":"PLoS Med"},{"key":"ref23","unstructured":"Study Quality Assessment Tool for Before-After (Pre-Post) Study with no Control Group. (2021). Accessed. 21-11-2023: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.46658\/JBIMES-20-08","article-title":"Chapter 7: Systematic reviews of etiology and risk","author":"Moola S","year":"2020","unstructured":"Moola S, Munn Z, Tufanaru C, et al.. Chapter 7: Systematic reviews of etiology and risk. JBI Manual for Evidence Synthesis. Aromataris E, Munn Z (ed): JBI, Adelaide; 2020. 10.46658\/JBIMES-20-08"},{"key":"ref25","article-title":"Botulinum toxin A in treatment of facial flushing","volume":"54","author":"Eshghi G","year":"2016","unstructured":"Eshghi G, Khezrian L, Alirezaei P. Botulinum toxin A in treatment of facial flushing. Acta Med Iran. 2016, 54:454-7.","journal-title":"Acta Med Iran"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001819","article-title":"Assessment of skin physiology change and safety after intradermal injections with botulinum toxin: a randomized, double-blind, placebo-controlled, split-face pilot study in rosacea patients with facial erythema","volume":"45","author":"Kim MJ","year":"2019","unstructured":"Kim MJ, Kim JH, Cheon HI, et al.. Assessment of skin physiology change and safety after intradermal injections with botulinum toxin: a randomized, double-blind, placebo-controlled, split-face pilot study in rosacea patients with facial erythema. Dermatol Surg. 2019, 45:1155-62. 10.1097\/DSS.0000000000001819","journal-title":"Dermatol Surg"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.5935\/scd1984-8773.20201243747","article-title":"Botulinum toxin for the treatment of erythema and flushing of rosacea with two different techniques: intradermal injections and facial electroporation","volume":"12","author":"Ga\u00f3n NQ","year":"2020","unstructured":"Ga\u00f3n NQ, Herane MI, Diaz MY, Morales MW. Botulinum toxin for the treatment of erythema and flushing of rosacea with two different techniques: intradermal injections and facial electroporation. Surg Cosmet Dermatol Rio de Janeiro. 2020, 12:326-31. 10.5935\/scd1984-8773.20201243747","journal-title":"Surg Cosmet Dermatol Rio de Janeiro"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15395","article-title":"A randomized, controlled, split-face study of botulinum toxin and broadband light for the treatment of erythematotelangiectatic rosacea","volume":"35","author":"Tong Y","year":"2022","unstructured":"Tong Y, Luo W, Gao Y, Liu L, Tang Q, Wa Q. A randomized, controlled, split-face study of botulinum toxin and broadband light for the treatment of erythematotelangiectatic rosacea. Dermatol Ther. 2022, 35:e15395. 10.1111\/dth.15395","journal-title":"Dermatol Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13976","article-title":"Pulsed dye laser followed by intradermal botulinum toxin type-A in the treatment of rosacea-associated erythema and flushing","volume":"33","author":"Al-Niaimi F","year":"2020","unstructured":"Al-Niaimi F, Glagoleva E, Araviiskaia E. Pulsed dye laser followed by intradermal botulinum toxin type-A in the treatment of rosacea-associated erythema and flushing. Dermatol Ther. 2020, 33:e13976. 10.1111\/dth.13976","journal-title":"Dermatol Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.5935\/scd1984-8773.2021130019","article-title":"Use of botulinum toxin for rosacea: a pilot study [Uso da toxina botul\u00ednica para ros\u00e1cea: estudo-piloto]","volume":"13","author":"Vasconcellos JB","year":"2021","unstructured":"Vasconcellos JB, Santos IO, Antelo DA. Use of botulinum toxin for rosacea: a pilot study [Uso da toxina botul\u00ednica para ros\u00e1cea: estudo-piloto]. Surg Cosmet Dermatol. 2021, 13:20210019. 10.5935\/scd1984-8773.2021130019","journal-title":"Surg Cosmet Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2018.30.6.688","article-title":"A pilot study to evaluate the efficacy and safety of treatment with botulinum toxin in patients with recalcitrant and persistent erythematotelangiectatic rosacea","volume":"30","author":"Park KY","year":"2018","unstructured":"Park KY, Kwon HJ, Kim JM, Jeong GJ, Kim BJ, Seo SJ, Kim MN. A pilot study to evaluate the efficacy and safety of treatment with botulinum toxin in patients with recalcitrant and persistent erythematotelangiectatic rosacea. Ann Dermatol. 2018, 30:688-93. 10.5021\/ad.2018.30.6.688","journal-title":"Ann Dermatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.14692","article-title":"Microbotox: a prospective evaluation of dermatological improvement in patients with mild-to-moderate acne and erythematotelangiectatic rosacea","volume":"21","author":"Calvisi L","year":"2022","unstructured":"Calvisi L, Diaspro A, Sito G. Microbotox: a prospective evaluation of dermatological improvement in patients with mild-to-moderate acne and erythematotelangiectatic rosacea. J Cosmet Dermatol. 2022, 21:3747-53. 10.1111\/jocd.14692","journal-title":"J Cosmet Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.23023","article-title":"The toxic edge-A novel treatment for refractory erythema and flushing of rosacea","volume":"51","author":"Friedman O","year":"2019","unstructured":"Friedman O, Koren A, Niv R, Mehrabi JN, Artzi O. The toxic edge-A novel treatment for refractory erythema and flushing of rosacea. Lasers Surg Med. 2019, 51:325-31. 10.1002\/lsm.23023","journal-title":"Lasers Surg Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.5935\/scd1984-8773.20181021131","article-title":"Prospective study for the treatment of rosacea flushing with botulinum toxin type A","volume":"10","author":"Silva LC","year":"2018","unstructured":"Silva LC, Ferreira IL, Silveira ML, Steiner D. Prospective study for the treatment of rosacea flushing with botulinum toxin type A. Surg Cosmet Dermatol Rio de Janeiro. 2018, 10:121-6. 10.5935\/scd1984-8773.20181021131","journal-title":"Surg Cosmet Dermatol Rio de Janeiro"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00784-0","article-title":"Botulinum toxin A alleviates persistent erythema and flushing in patients with erythema telangiectasia rosacea","volume":"12","author":"Yang R","year":"2022","unstructured":"Yang R, Liu C, Liu W, Luo J, Cheng S, Mu X. Botulinum toxin A alleviates persistent erythema and flushing in patients with erythema telangiectasia rosacea. Dermatol Ther (Heidelb). 2022, 12:2285-94. 10.1007\/s13555-022-00784-0","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.25251\/skin.6.5.16","article-title":"Turning down the fire: the role of botulinum toxin microdroplets in refractory rosacea erythema","volume":"6","author":"Babadjouni A","year":"2022","unstructured":"Babadjouni A, Phong CH, Raffi J, Mesinkovska NA. Turning down the fire: the role of botulinum toxin microdroplets in refractory rosacea erythema. SKIN: J Cutan Med. 2022, 6:437-40. 10.25251\/skin.6.5.16","journal-title":"SKIN: J Cutan Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.014","article-title":"Mesotherapy with botulinum toxin for the treatment of refractory vascular and papulopustular rosacea","volume":"88","author":"Bharti J","year":"2023","unstructured":"Bharti J, Sonthalia S, Jakhar D. Mesotherapy with botulinum toxin for the treatment of refractory vascular and papulopustular rosacea. J Am Acad Dermatol. 2023, 88:e295-6. 10.1016\/j.jaad.2018.05.014","journal-title":"J Am Acad Dermatol"},{"key":"ref38","article-title":"Botulinum toxin: an effective treatment for flushing and persistent erythema in rosacea","volume":"14","author":"Luque A","year":"2021","unstructured":"Luque A, Rojas AP, Ortiz-Florez A, Perez-Bernal J. Botulinum toxin: an effective treatment for flushing and persistent erythema in rosacea. J Clin Aesthet Dermatol. 2021, 14:42-5.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S194074","article-title":"Conventional and novel treatment modalities in rosacea","volume":"13","author":"Engin B","year":"2020","unstructured":"Engin B, \u00d6zkoca D, Kutlubay Z, Serdaro\u011flu S. Conventional and novel treatment modalities in rosacea. Clin Cosmet Investig Dermatol. 2020, 13:179-86. 10.2147\/CCID.S194074","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12903","article-title":"Global rosacea treatment guidelines and expert consensus points: the differences","volume":"18","author":"Juliandri J","year":"2019","unstructured":"Juliandri J, Wang X, Liu Z, Zhang J, Xu Y, Yuan C. Global rosacea treatment guidelines and expert consensus points: the differences. J Cosmet Dermatol. 2019, 18:960-5. 10.1111\/jocd.12903","journal-title":"J Cosmet Dermatol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S307013","article-title":"Use of botulinum toxin in treating rosacea: a systematic review","volume":"14","author":"Zhang H","year":"2021","unstructured":"Zhang H, Tang K, Wang Y, Fang R, Sun Q. Use of botulinum toxin in treating rosacea: a systematic review. Clin Cosmet Investig Dermatol. 2021, 14:407-17. 10.2147\/CCID.S307013","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.01071.2005","article-title":"In vivo mechanisms of cutaneous vasodilation and vasoconstriction in humans during thermoregulatory challenges","volume":"100","author":"Kellogg DL Jr","year":"2006","unstructured":"Kellogg DL Jr. In vivo mechanisms of cutaneous vasodilation and vasoconstriction in humans during thermoregulatory challenges. J Appl Physiol (1985). 2006, 100:1709-18. 10.1152\/japplphysiol.01071.2005","journal-title":"J Appl Physiol (1985)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.4065\/78.5.603","article-title":"Skin blood flow in adult human thermoregulation: how it works, when it does not, and why","volume":"78","author":"Charkoudian N","year":"2003","unstructured":"Charkoudian N. Skin blood flow in adult human thermoregulation: how it works, when it does not, and why. Mayo Clin Proc. 2003, 78:603-12. 10.4065\/78.5.603","journal-title":"Mayo Clin Proc"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.4103\/JCAS.JCAS_197_20","article-title":"Botulinum toxin for scalp dysesthesia","volume":"15","author":"Phan K","year":"2022","unstructured":"Phan K, Lin MJ. Botulinum toxin for scalp dysesthesia. J Cutan Aesthet Surg. 2022, 15:95-6. 10.4103\/JCAS.JCAS_197_20","journal-title":"J Cutan Aesthet Surg"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1111\/dsu.12405","article-title":"Diffusion of two botulinum toxins type A on the forehead: double-blinded, randomized, controlled study","volume":"40","author":"Jiang HY","year":"2014","unstructured":"Jiang HY, Chen S, Zhou J, Leung KK, Yu P. Diffusion of two botulinum toxins type A on the forehead: double-blinded, randomized, controlled study. Dermatol Surg. 2014, 40:184-92. 10.1111\/dsu.12405","journal-title":"Dermatol Surg"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-011-1179-z","article-title":"Comparison of the spread of three botulinum toxin type A preparations","volume":"304","author":"Kerscher M","year":"2012","unstructured":"Kerscher M, Roll S, Becker A, Wigger-Alberti W. Comparison of the spread of three botulinum toxin type A preparations. Arch Dermatol Res. 2012, 304:155-61. 10.1007\/s00403-011-1179-z","journal-title":"Arch Dermatol Res"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0183","article-title":"In vivo estimation of stratum corneum thickness from water concentration profiles obtained with Raman spectroscopy","volume":"87","author":"Egawa M","year":"2007","unstructured":"Egawa M, Hirao T, Takahashi M. In vivo estimation of stratum corneum thickness from water concentration profiles obtained with Raman spectroscopy. Acta Derm Venereol. 2007, 87:4-8. 10.2340\/00015555-0183","journal-title":"Acta Derm Venereol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2013.03.019","article-title":"Next generation intra- and transdermal therapeutic systems: using non- and minimally-invasive technologies to increase drug delivery into and across the skin","volume":"50","author":"Gratieri T","year":"2013","unstructured":"Gratieri T, Alberti I, Lapteva M, Kalia YN. Next generation intra- and transdermal therapeutic systems: using non- and minimally-invasive technologies to increase drug delivery into and across the skin. Eur J Pharm Sci. 2013, 50:609-22. 10.1016\/j.ejps.2013.03.019","journal-title":"Eur J Pharm Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/211037-the-efficacy-and-safety-of-botulinum-toxin-a-for-the-treatment-of-rosacea-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T15:06:14Z","timestamp":1707491174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/211037-the-efficacy-and-safety-of-botulinum-toxin-a-for-the-treatment-of-rosacea-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,29]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.51304","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,29]]}}}